Addyi Efficacy Plateau: How to Manage Flibanserin Titration and Optimize Response

What Is the FDA-Approved Flibanserin Dose, and Can It Be Escalated?

Flibanserin is approved at exactly one dose: 100 mg taken orally at bedtime. The FDA label does not authorize escalation beyond 100 mg, and no Phase 3 data support a 200 mg regimen in premenopausal women with HSDD. The ceiling is pharmacological, not arbitrary. Higher exposures sharply increase CNS depression, hypotension, and syncope without meaningful additional efficacy signal.

Why the Dose Is Fixed

Flibanserin acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, with secondary dopamine D4 agonism. Its therapeutic window is narrow. The BEGONIA trial (NCT01015625), published in the Journal of Sexual Medicine in 2014, randomized 1,378 premenopausal women to 100 mg once nightly or placebo for 24 weeks. The 100 mg bedtime arm produced a statistically significant increase in satisfying sexual events (SSEs) of +0.49 per month over placebo (P<0.05) alongside improvements on the Female Sexual Function Index desire domain [1]. Doses above 100 mg were not evaluated in the key program because earlier Phase 2 work showed a flat dose-response curve above that threshold with escalating adverse-event rates.

What "Plateau" Actually Means Clinically

An efficacy plateau with flibanserin describes one of two scenarios: (1) a patient achieves partial response in the first 4 weeks but gains no further improvement by week 8, or (2) a patient who initially responded well reports a return to near-baseline desire over subsequent months. These two patterns have different mechanisms and require different responses from the prescriber.

The 8-Week Rule: FDA's Built-In Assessment Point

The FDA label for Addyi specifies that prescribers should evaluate response at 8 weeks. Patients who do not show a meaningful increase in desire or a reduction in distress related to low desire by that checkpoint should discontinue the medication [2]. This is not a soft recommendation. The Addyi REMS program, maintained because of the serious hypotension and syncope risk particularly when alcohol is consumed, requires that prescribers counsel patients on this timeline at enrollment.

Defining "Meaningful Response"

The FDA label does not specify a numeric SSE cutoff for the 8-week decision. Clinically, the standard applied in the BEGONIA trial was a patient-reported improvement on the eDiary SSE count and a decrease in the Female Sexual Distress Scale-Revised (FSDS-R) total score [1]. A reasonable clinical threshold is at least one additional SSE per month above baseline combined with patient-reported reduction in distress. If neither is present at 8 weeks, the risk-benefit calculation favors stopping.

When to Extend Beyond 8 Weeks

The 8-week cut-point applies to patients with zero response. Partial responders, meaning those with measurable but incomplete improvement, may benefit from continuing to 12 or 16 weeks while addressing modifiable factors (see below). The prescriber must document the rationale clearly, given the REMS obligation.

Modifiable Factors That Mimic a Plateau

Before concluding that flibanserin has failed, systematically review the four most common reasons a patient may under-respond.

1. Timing Errors

Flibanserin must be taken at bedtime, not during waking hours. The bedtime requirement exists because peak plasma concentration (Cmax reached in approximately 45 minutes) coincides with peak CNS depression risk. Patients who shift dosing to mid-evening or take the tablet intermittently will see erratic exposure and inconsistent pharmacodynamic effect. Confirm adherence with a 30-day medication diary before labeling a patient a non-responder.

2. CYP2C19 and CYP3A4 Inhibitor Co-Administration

Flibanserin is a CYP3A4 substrate and a CYP2C19 substrate. Concomitant use of moderate or strong CYP3A4 inhibitors, such as fluconazole, ketoconazole, clarithromycin, or ritonavir, is contraindicated by the FDA label because these agents can increase flibanserin AUC by 4.5-fold, dramatically raising CNS and cardiovascular adverse event risk [2]. Even moderate CYP2C19 inhibitors, including omeprazole and esomeprazole, raise exposure meaningfully. A patient started on a proton-pump inhibitor after initiating flibanserin may appear to "plateau" because increasing side effects, including somnolence and nausea, lead to self-reduced adherence. Review the full medication list at every follow-up.

3. Alcohol Use

The FDA label carries a boxed warning: alcohol consumed within two hours before or after flibanserin significantly potentiates hypotension and syncope [2]. Patients who were initially abstinent and later resume moderate alcohol use may drop doses to avoid feeling unwell, compressing their actual exposure. Ask directly about alcohol use at each visit.

4. Comorbid Untreated Contributors

HSDD in premenopausal women is frequently multifactorial. The North American Menopause Society (NAMS) 2022 position statement on sexual health notes that relationship distress, untreated depression, pain disorders such as vulvodynia or endometriosis, and partner sexual dysfunction all substantially reduce treatment response to any pharmacologic agent used for desire disorders [3]. Flibanserin is not a relationship intervention. If a patient's plateau coincides with a new stressor or unaddressed pain, addressing that factor may restore response without any medication change.

Pharmacokinetic Basis for the Plateau: Why You Cannot Simply Double the Dose

The table below outlines the pharmacokinetic and pharmacodynamic reasoning that makes dose escalation above 100 mg clinically untenable, organized as a decision framework for the prescriber.

| Parameter | 100 mg (approved) | Theoretical 200 mg | |---|---|---| | Cmax (ng/mL) | ~250 | ~500 (estimated linear) | | CNS depression risk | Moderate; managed by bedtime timing | High; daytime carryover likely | | Hypotension risk (fasting) | Low-moderate | High | | Efficacy increment vs. 100 mg | Established (+0.49 SSE/month vs. Placebo) | No Phase 3 data; flat dose-response in Phase 2 | | FDA approval status | Approved | Not approved |

The Phase 2 program for flibanserin evaluated doses from 25 mg once daily to 100 mg twice daily before the 100 mg once-nightly regimen was selected. The twice-daily 50 mg arm, which provides similar total daily exposure, showed inferior efficacy to 100 mg once nightly, suggesting that peak concentration, not just total AUC, may drive the CNS target engagement relevant to desire [4]. That pharmacokinetic insight is why bedtime timing is therapeutic, not merely a safety accommodation.

What the BEGONIA Trial Tells Us About Early vs. Late Responders

BEGONIA (NCT01015625) enrolled 1,378 premenopausal women and followed them for 24 weeks at 100 mg once nightly [1]. Several findings are directly relevant to plateau management.

SSE Trajectory Over 24 Weeks

Response in the active arm was not linear. SSE gains were largest between weeks 4 and 8, with the curve flattening between weeks 12 and 24. This pattern suggests that patients who show no improvement by week 8 are unlikely to show late-onset response, supporting the FDA's 8-week discontinuation guidance.

Dropout Rates and Tolerability

The most common adverse events in BEGONIA were somnolence (reported by 16% of active-arm participants), dizziness (11%), and nausea (10%) [1]. Most dropouts related to adverse events occurred in the first 4 weeks. Patients who tolerate the first month are substantially more likely to complete 24 weeks, which has a practical implication: a patient reporting somnolence in week 2 should be counseled to persist through week 4 before attributing the side effect to a stable problem, because tolerance to CNS depression typically develops.

Desire Score Outcomes

On the Female Sexual Function Index (FSFI) desire domain, the BEGONIA active arm scored a mean improvement of 0.6 points over placebo at 24 weeks (P<0.05) [1]. This is a modest but patient-meaningful effect for a disorder with very limited pharmacologic options. Prescribers should frame this expectation at treatment initiation, reducing the likelihood that a patient interprets a moderate improvement as a "plateau."

When to Stop: A Structured Discontinuation Protocol

Stopping flibanserin is straightforward pharmacokinetically. There is no taper requirement. The half-life is approximately 11 hours, so plasma levels are negligible within 48 to 72 hours of the last dose [2]. The clinical decision, however, requires documentation under the REMS.

Step 1: Confirm the Plateau Is Real

Before discontinuing, confirm the patient has taken 100 mg at bedtime consistently for at least 8 weeks, has abstained from alcohol, is not on a CYP3A4 or CYP2C19 inhibitor, and has no unaddressed comorbid contributors. If any of these conditions are unmet, address them before declaring treatment failure.

Step 2: Use the FSDS-R as an Anchor

The Female Sexual Distress Scale-Revised is a validated 13-item patient-reported outcome used in the BEGONIA trial and the FDA's efficacy analysis [1]. A score of 11 or above indicates clinically significant distress. If a patient's FSDS-R score has not decreased by at least 3 to 4 points from baseline at 8 weeks, and her SSE count is unchanged, discontinuation is appropriate.

Step 3: Document in the REMS System

The Addyi REMS requires prescriber certification. When discontinuing, update the patient's status in the REMS registry and provide the patient with written information about stopping. No dose reduction before stopping is needed [2].

Alternative Strategies After Flibanserin Failure

If flibanserin fails at 8 weeks and modifiable factors have been addressed, two evidence-based paths exist.

Bremelanotide (Vyleesi)

Bremelanotide is a melanocortin receptor agonist approved by the FDA in June 2019 for HSDD in premenopausal women. It is administered as a 1.75 mg subcutaneous injection approximately 45 minutes before anticipated sexual activity, on an as-needed basis rather than daily [5]. The RECONNECT trial program (N=1,247 combined across Study 1 and Study 2) showed statistically significant improvements in desire and distress compared to placebo at 24 weeks [5]. Bremelanotide does not require bedtime dosing or alcohol restriction, which makes it a practical alternative for patients whose flibanserin failure was partly adherence-driven.

Sex Therapy and Combined Approaches

The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 clinical practice guideline on HSDD recommends psychosexual therapy as a first-line or adjunctive intervention regardless of pharmacologic treatment [6]. A 2016 systematic review in the Journal of Sexual Medicine found that cognitive-behavioral sex therapy produced effect sizes of 0.6 to 0.9 on desire outcomes, exceeding the pharmacologic effect sizes seen with flibanserin [7]. Combining pharmacotherapy with sex therapy is not redundant. The two approaches act through different mechanisms: medication addresses the neurobiological substrate, while therapy addresses cognitive, relational, and contextual drivers.

Practical Prescribing Checklist Before Labeling a Patient a Non-Responder

The following checklist operationalizes the above evidence into a visit-ready tool.

• Confirm 100 mg taken at bedtime (not earlier in the evening) on at least 5 of 7 nights per week for 8 continuous weeks.
• Review full medication list for CYP3A4 and CYP2C19 inhibitors, including over-the-counter antifungals and proton-pump inhibitors.
• Screen for alcohol use in the 2-hour window before or after dosing.
• Administer FSDS-R and compare to baseline score.
• Count SSEs from the patient's eDiary or self-report for the past 4 weeks versus the 4 weeks before starting.
• Screen for new or worsening depression, relationship conflict, pain disorders, or partner dysfunction.
• If all boxes above are checked and no improvement is documented, discontinue per FDA label and REMS guidance and discuss bremelanotide or referral to a certified sex therapist.

Frequently Asked Questions